Table 3.

Endosialin expression in human clinical cancer specimens

Tissue preservationTissue typePercentage of specimens with endosialin-positive vasculaturePercentage of specimens with endosialin-positive tumor cellsPercentage of specimens with endosialin-positive stromal cells
FFPEBladder cancer100 (10/10)0 (0/10)0 (0/10)
Breast cancer30 (3/10)0 (0/10)0 (0/10)
Colon cancer30 (3/10)0 (0/10)0 (0/10)
Endometrial cancer50 (5/10)0 (0/10)0 (0/10)
Gastric cancer33 (3/9)0 (0/9)0 (0/9)
Head and neck cancer10 (1/10)0 (0/10)0 (0/10)
Liver cancer10 (1/10)0 (0/10)0 (0/10)
Lung cancer40 (4/10)0 (0/10)0 (0/10)
Ovarian cancer27 (3/11)0 (0/11)0 (0/11)
Prostate cancer0 (0/10)0 (0/10)0 (0/10)
Total FFPE carcinoma33 (33/100)0 (0/100)0 (0/100)
Angiosarcoma57 (4/7)14 (1/7)29 (2/7)
Ewing's sarcoma67 (6/9)33 (3/9)11 (1/9)
Fibrosarcoma75 (6/8)75 (6/8)0 (0/8)
GIST60 (6/10)30 (3/10)20 (2/10)
Liposarcoma80 (8/10)70 (7/10)10 (1/10)
MFH91 (10/11)73 (8/11)27 (3/11)
Osteosarcoma100 (11/11)64 (7/11)73 (8/11)
Rhabdomyosarcoma90 (9/10)10 (1/10)0 (0/10)
Synovial sarcoma70 (7/10)80 (8/10)20 (2/10)
Total FFPE sarcoma78 (67/86)51 (44/86)22 (19/86)
FrozenBladder cancer100 (7/7)0 (0/7)29 (2/7)
Breast cancer70 (7/10)0 (0/10)40 (4/10)
Colon cancer100 (5/5)0 (0/5)100 (5/5)
Endometrial cancer100 (10/10)0 (0/10)50 (5/10)
Gastric cancer100 (7/7)0 (0/7)100 (7/7)
Lung cancer80 (4/5)0 (0/5)20 (1/5)
Ovarian cancer100 (7/7)0 (0/7)71 (2/7)
Renal cancer100 (7/7)0 (0/7)29 (2/7)
Total frozen carcinoma93 (54/58)0 (0/58)53 (31/58)
Total frozen sarcoma100 (6/6)50 (3/6)100 (6/6)
  • NOTE: The percentage of samples of each tumor type having endosialin-positive vasculature, malignant cells, and stromal cells is listed for each cancer subtype surveyed by immunohistochemistry staining for endosialin. Each tumor specimen was scored and examined independently by two pathologists.